SEC Form 4 · accession 0001209191-18-011097
TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Sabag
Officer — EVP, Global Human Resources
Period of report
Feb 14, 2018
Accepted (ET)
Feb 20, 2018 · 8:31 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Feb 14, 2018 | S | 2,050 | $18.45 | D | 44,517 | D | |
| Ordinary SharesF1,F3 | Feb 15, 2018 | S | 3,000 | $20.52 | D | 41,517 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.43 to $18.47.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.54 to $20.50.
Remarks
The Ordinary Shares were sold in New Israeli Shekels. The prices have been converted to U.S. dollars using the daily representative rate of exchange published by the Bank of Israel on the transaction date. Reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.